
Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
A Couple of Modest Guitars for 2024 - 2
Exclusive-Drugmakers raise US prices on 350 medicines despite pressure from Trump - 3
Reporter's Notebook: The Post embeds with foreign armies visiting the IDF - 4
These are the Fastest Italian Sports Cars - 5
7 Peculiar Ways Of starting Your Imagination: Motivation Has Never Been This Good times
Winter storm headed for Midwest to Northeast. Here's how much snow to expect.
Top Frozen yogurt Flavor: Cast Your Vote!
Hamas propaganda expert explains Israel's internal conflicts influenced Hamas's Oct. 7 assault
The Best 20 Photography Instagram Records to Follow
A Past filled with Old Civilizations: The World's Most established Societies
New method spots signs of Earth's primordial life in ancient rocks
Chicago reports first rabies-positive dog in 61 years. What we know.
Illustrations Gained from a Crosscountry Excursion
Instructions to Pick the Right Gold Speculation Procedure: Exploring the Market













